8-K filed Jul 29, 2026 at 07:00 ET
Teva reported Q2 2026 revenue of $4.14B (-1% YoY) and non-GAAP EPS of $0.02, both below consensus ($0.05). The headline GAAP loss of $0.49/share was driven by a $726M Emalex acquisition charge ($724M IPR&D). However, key innovative brands (AUSTEDO, AJOVY, UZEDY) collectively grew 43% YoY in local currency to over $1B, and the company raised its 2026 revenue outlook for all three brands. Full-year non-GAAP EPS guidance of $1.91-$2.11 was maintained, implying a strong H2 ramp. A credit rating upgrade to investment-grade BBB- by Fitch and the planned ADS-to-direct-listing conversion add to the positive narrative.